Gain Therapeutics (GANX) vs Spero Therapeutics (SPRO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Gain Therapeutics (GANX) has outperformed Spero Therapeutics (SPRO) over the past year, losing 17.3% versus a loss of 45.8%. Over five years, GANX leads with a -75.9% price change compared with -93.1% for SPRO. Gain Therapeutics is the larger company by market cap ($70.5 million vs $66.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GANX | SPRO |
|---|---|---|
| Share price | $1.62 | $1.14 |
| Market cap | $70.48M | $66.39M |
| 1-day change | -3.29% | -2.56% |
| YTD return | -48.14% | -49.79% |
| 1-year return | -17.33% | -45.83% |
| 5-year return | -75.94% | -93.13% |
| P/E ratio (TTM) | — | 8.14 |
| EPS (TTM) | $-0.50 | $0.14 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.34 | $3.08 |
| 52-week low | $1.53 | $1.08 |
| Distance from 52-week high | -62.79% | -62.99% |
| Average volume | 497.54K | 1.20M |
| Shares outstanding | 43.64M | 58.23M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GANX has outperformed SPRO by 28.5 percentage points over the past year.
GANX vs SPRO FAQ
Which is bigger, Gain Therapeutics or Spero Therapeutics?
Gain Therapeutics (GANX) is larger, with a market capitalization of $70.48M compared with $66.39M for Spero Therapeutics (SPRO).
Which stock has performed better over the past year, GANX or SPRO?
GANX returned -17.33% over the past 12 months, compared with -45.83% for SPRO (price return, excluding dividends). Past performance does not predict future results.
Are Gain Therapeutics and Spero Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.